Skip to main content

Table 1 Baseline demographics and characteristics of eptinezumab-treated ≥ 50–< 75% and ≥ 75% migraine responders

From: Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials

  Eptinezumab 100 mg Eptinezumab 300 mg Eptinezumab Pooled
PROMISE-1 (EM) ≥ 50–< 75%
N = 61
≥ 75%
N = 49
≥ 50–< 75%
N = 59
≥ 75%
N = 66
≥ 50–< 75%
N = 120
≥ 75%
N = 115
Mean age, years (SD) 40.5 (10.09) 39.1 (12.18) 40.1 (13.03) 40.1 (11.21) 40.3 (11.58) 39.7 (11.59)
Sex, n (%)
 Female 47 (77.0%) 39 (79.6%) 52 (88.1%) 57 (86.4%) 99 (82.5%) 96 (83.5%)
 Male 14 (23.0%) 10 (20.4%) 7 (11.9%) 9 (13.6%) 21 (17.5%) 19 (16.5%)
Race, n (%)
 White 53 (86.9%) 43 (87.8%) 52 (88.1%) 58 (87.9%) 105 (87.5%) 101 (87.8%)
 Black or African American 6 (9.8%) 2 (4.1%) 5 (8.5%) 7 (10.6%) 11 (9.2%) 9 (7.8%)
 Other 2 (3.3%) 4 (8.2%) 2 (3.4%) 1 (1.5%) 4 (3.3%) 5 (4.3%)
Mean (SD) BMI, kg/m2 29.5 (6.56) 28.0 (7.48) 27.4 (6.59) 29.8 (7.28) 28.4 (6.63) 29.0 (7.39)
Mean (SD) age at diagnosis, years 23.4 (11.50) 19.9 (9.24) 22.7 (10.28) 21.0 (9.39) 23.1 (10.88) 20.5 (9.30)
Mean (SD) duration of migraine diagnosis, years 17.0 (12.16) 19.3 (10.99) 17.4 (13.10) 19.0 (11.22) 17.2 (12.58) 19.1 (11.07)
Mean (SD) baseline migraine days 8.3 (2.66) 8.8 (2.85) 9.0 (2.79) 8.5 (2.86) 8.7 (2.73) 8.6 (2.84)
Mean (SD) baseline headache days 9.2 (2.77) 10.0 (2.65) 10.0 (2.74) 10.4 (3.32) 9.6 (2.77) 10.3 (3.05)
PROMISE-2 (CM) ≥ 50–< 75%
N = 110
≥ 75%
N = 95
≥ 50–< 75%
N = 99
≥ 75%
N = 116
≥ 50–< 75%
N = 209
≥ 75%
N = 211
Mean age, years (SD) 38.3 (11.37) 43.9 (11.18) 42.1 (10.95) 41.1 (10.06) 40.1 (11.31) 42.3 (10.64)
Sex, n (%)
 Female 98 (89.1%) 80 (84.2%) 92 (92.9%) 102 (87.9%) 190 (90.9%) 182 (86.3%)
 Male 38.3 (11.37) 15 (15.8%) 7 (7.1%) 14 (12.1%) 19 (9.1%) 29 (13.7%)
Race, n (%)
 White 106 (96.4%) 90 (94.7%) 91 (91.9%) 108 (93.1%) 197 (94.3%) 198 (93.8%)
 Black or African American 4 (3.6%) 5 (5.3%) 6 (6.1%) 6 (5.2%) 10 (4.8%) 11 (5.2%)
 Other 0 0 2 (2.0%) 2 (1.7%) 2 (1.0%) 2 (0.9%)
Mean (SD) BMI, kg/m2 25.4 (4.77) 26.3 (4.11) 25.9 (4.25) 26.5 (4.87) 25.6 (4.53) 26.4 (4.53)
Mean (SD) age at diagnosis, years 20.7 (9.39) 24.1 (10.13) 22.0 (9.52) 23.0 (9.43) 21.3 (9.46) 23.5 (9.74)
Mean (SD) duration of migraine diagnosis, years 17.7 (11.02) 19.7 (12.43) 20.1 (12.71) 18.1 (11.25) 18.8 (11.88) 18.8 (11.80)
Mean (SD) duration of chronic migraine, years 10.4 (11.19) 10.3 (12.30) 13.2 (12.38) 10.8 (11.01) 11.7 (11.82) 10.6 (11.58)
Mean (SD) baseline migraine days 16.1 (4.43) 15.7 (4.18) 15.5 (4.64) 15.0 (4.42) 15.8 (4.53) 15.3 (4.32)
Mean (SD) baseline headache days 20.2 (3.01) 19.6 (2.54) 19.8 (3.09) 20.0 (3.11) 20.0 (3.05) 19.8 (2.86)
Medication-overuse headache diagnosis, n (%) 46 (41.8%) 38 (40.0%) 47 (47.5%) 44 (37.9%) 93 (44.5%) 82 (38.9%)
  1. A ≥ 50–< 75% migraine responder was defined as a patient who achieved a ≥ 50–< 75% reduction in mean monthly migraine days over Weeks 1–12. A ≥ 75% migraine responder was defined as a patient who achieved a ≥ 75% reduction in mean monthly migraine days over Weeks 1–12. BMI, body mass index; CM, chronic migraine; EM, episodic migraine; SD, standard deviation